Track Features Latest Science on Environmental Hazards, Epidemiology, Disparities, and More
Babalola Faseru, MBChB, MPH, CPHDr. Babalola Faseru highlights key studies to be discussed during the Risk Factors, Risk Reduction & Tobacco Control track. Read more
Nearly 20 workshops have been planned for a wide range of specialties and interests, such as early-career research, genomics, communication, radiation, and more. Read more
IASLC Announces 2024 Class of Patient Research Advocates
Erin JungmeyerEach year, IASLC’S STARS program equips a new cohort of patients and caregivers with the skills needed to participate in thoracic oncology research. Read more
IASLC to Celebrate 50 Years of International Collaboration, Education in Thoracic Oncology at WCLC 2024
Erin JungmeyerThe chairs of the 2024 World Conference on Lung Cancer say this year’s program not only highlights the latest groundbreaking advances in thoracic oncology, it includes opportunities to look back at the progress that has been made since the IASLC’s first meeting. Read more
Celebrate 5 Decades of the World Conference on Lung Cancer in San Diego’s Historic Gaslamp Quarter
Erin JungmeyerCome dressed in the style of your favorite decade from the ‘70s to today when you join your colleagues for an unforgettable block party to honor 50 years of progress in lung cancer. Read more
2024 IASLC Academy to Once Again Compete in Amazing Case Race
Erin JungmeyerAfter a successful inaugural year in 2023, participants have once again crafted case summaries, and WCLC 2024 attendees will help choose the winning cases. Read more
Stay active during your time in San Diego by taking part in IASLC’S Wellness Challenge, Step It Up for Research. Read more
Know Before You Go: What You Need to Know to Get to—and Navigate—San Diego
Erin JungmeyerWith the 2024 World Conference on Lung Cancer less than a month away, now is the time to make sure you know where you’re headed and how to get there. Read more
BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population
John AustinWhile the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population. Read more
Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2
Erin JungmeyerIn an interview with ILCN, principal investigator Dr. Jeffrey Bradley discusses his thoughts on why the trial proved negative. Read more